[1] Gower E, Estes C, Blach S. et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol, 2014, 61: S45-57.
[2] Ampuero J, Romero-Gomez M, Reddy KR. HCV genotype 3 the new treatment challenge. Aliment Pharmacol Ther, 2014, 39: 686-698.
[3] Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat, 2011, 18: e516-e522.
[4] Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase Ⅲ study. Hepatology, 2015, 61: 1127-1135.
[5] Sorbo MC, Cento V, Di Maio VC, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist Updat, 2018, 37:17-39.
[6] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2015年更新版). 临床肝胆病杂志, 2015, 31: 1961-1979.
[7] 陈若蝉, 刘振国, 范学工. DAA与HCC——丙肝治疗新时代的挑战.中国感染控制杂志, 2018, 17: 369-372.
[8] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol, 2017, 66: 153-194.
[9] Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol, 2018, 16: 417-426.
[10] Banerjee D, Reddy KR. Safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther, 2016, 43: 674-696. |
